Lung cancer involving neighboring structures is classified

Size: px
Start display at page:

Download "Lung cancer involving neighboring structures is classified"

Transcription

1 GENERAL THORACIC Subcategorization of Resectable Non-Small Cell Lung Cancer Involving Neighboring Structures Noriaki Sakakura, MD, Shoichi Mori, MD, Futoshi Ishiguro, MD, Takayuki Fukui, MD, Shunzo Hatooka, MD, Masayuki Shinoda, MD, Kohei Yokoi, MD, and Tetsuya Mitsudomi, MD Department of Thoracic Surgery, Aichi Cancer Center Hospital, and Division of Thoracic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan Background. Although the prognoses of patients with resectable lung cancer involving neighboring structures vary, the current tumor-nodes-metastasis (TNM) classification system does not elucidate criteria for tumor subcategorization. Methods. We studied 196 consecutive patients who underwent resection of non-small cell lung cancer involving neighboring structures at the Aichi Cancer Center Hospital and were diagnosed as pathologic T3 diseases using the current staging system. Tumors were divided into six groups based on the involved neighboring structures: parietal or mediastinal pleura, subpleural soft tissue, ribs, main bronchus, pericardium, and diaphragm. Results. The overall 5-year survival rate was 39.8%. The survival rates for the six groups were: pleura (n 62), 54.8%; subpleural soft tissue (n 50), 30.0%; rib (n 25), 24.0%; main bronchus (n 33), 48.5%; pericardium (n 14), 21.4%; and diaphragm (n 12), 33.3%. The combined pleura and bronchus groups (n 95) demonstrated significantly better survival outcome than the other groups (n 101): 52.6% and 27.7%, respectively p ( ). Furthermore, among 108 patients with pt3n0 (stage IIB) disease, the prognostic difference between the pleura and bronchus groups (n 50) and the other groups (n 58) was significant: 64.0% and 25.9%, respectively p ( < ). Similar results were confirmed in patients with complete resection (n 159). Conclusions. Subcategorization of resectable lung cancer involving neighboring structures resulted in tumor groups infiltrating pleura or main bronchus, and those involving subpleural structures, pericardium, or diaphragm. (Ann Thorac Surg 2008;86: ) 2008 by The Society of Thoracic Surgeons Lung cancer involving neighboring structures is classified as T3 or T4 disease in the current tumor-a heterogeneous group [11, 12]. Furthermore, although bronchus within 2 cm of the carina are considered to be nodes-metastasis (TNM) classification for lung cancer, tumors involving the diaphragm are defined as T3, some last revised in 1997 [1, 2]. The T3 tumors are defined as authors have postulated that this classification should be those involving resectable structures (chest wall, pericardium, diaphragm, or main bronchus within 2 cm of the The T3N0M0 tumors have been shifted from stage IIIA to revised [13 15]. carina), while T4 tumors are those invading organs con-iisidered to be unresectable (heart, great vessels, trachea neity of T3 tumors, however, the classification of all in the current staging system [1, 2]. Given the heteroge- and carina, esophagus, or vertebral body). T3N0M0 tumors into stage IIB has been considered to Numerous studies have reported on the various aspects of the prognoses of T3 diseases. Among the tumorssystem was finally proposed by the International Associa- require further examination [10]. The next TNM staging involving the chest wall, those with infiltration limited tion for the Study of Lung Cancer (IASLC) International to the parietal pleura reportedly have better prognoses Staging Committee in 2007 [16, 17]. In this system, current than those with involvement extending to subpleural soft T2 tumors larger than 7 cm and current T4 tumors with tissue or ribs [3 5]. In contrast, some reports suggest that pulmonary metastases in the same lobe are both categorized as T3 lesions, together with the current T3 tumors. The the depth of invasion does not influence prognoses [6 9]. Regarding tumors invading the mediastinum, it has been treatment strategies for lung cancer patients will be revised, suggested that patients with such tumors have worse in the near future, on the basis of this staging system. Here, prognoses than those with tumors invading the osseous chest wall [10]. Alternatively, tumors involving the main Accepted for publication June 9, Presented at the Forty-fourth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 28 30, Address correspondence to Dr Sakakura, Division of Thoracic Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, , Japan; nskkr@med.nagoya-u.ac.jp. we focused on resectable lung cancer involving neighboring structures and developed a subcategorization criteria for such tumors. Patients and Methods This study was approved by the Institutional Review Board of the Aichi Cancer Center Hospital, and patient consent was waived because of the study s retrospective 2008 by The Society of Thoracic Surgeons /08/$34.00 Published by Elsevier Inc doi: /j.athoracsur

2 Ann Thorac Surg SAKAKURA ET AL 2008;86: SUBCATEGORIZATION BY INVOLVED STRUCTURES Table 1. Patient Characteristics Variables All Patients (n 196) Patients With Complete Resection (n 159) Median age (years) (range) 63.0 (28 81) 63.6 (28 81) Gender: Male Female Histology: Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Adenosquamous carcinoma 7 6 Surgical procedure: Lobectomy Peumonectomy Segmentectomy 9 2 Chemotherapy and radiotherapy: Preoperative Yes No Postoperative Yes No Tumor size: 5 cm cm Node status: N N N T3 structures involved: Pleura (parietal or mediastinal) Subpleural soft tissue Ribs Main bronchus Pericardium Diaphragm 12 9 design. We studied 196 consecutive patients who underwent resection of non-small cell lung cancer involving neighboring structures between January 1980 and December 2002 at the Aichi Cancer Center Hospital and were diagnosed as pathologic T3 (pt3) diseases using the current TNM staging system. The characteristics of the patients are shown in Table 1. Histologic typings were assigned according to the World Health Organization criteria [18]. Tumors were divided into six groups based on the involved neighboring structures that were pathologically determined: parietal or mediastinal pleura, subpleural soft tissue, ribs, main bronchus, pericardium, and diaphragm. Based on the neighboring structures involved, the groups were defined as follows: pleura group, tumors infiltrating parietal or mediastinal pleura without involvement of deeper structures; subpleural soft tissue 1077 group, tumors involving subpleural fat tissues, nerves, small vessels, and intercostal muscles; rib group, tumors involving ribs regardless of whether their involvement is limited to the periostea or extends to the bone cortex; main bronchus group, tumors invading main bronchus within 2 cm of the carina; pericardium group, tumors involving pericardium regardless of whether their involvement is limited to or penetrates the pericardium; and diaphragm group, tumors involving the diaphragm regardless of whether their involvement is limited to diaphragmatic pleura or extends to diaphragmatic muscle layer. The first three groups are categorized based on the degree of the depth of invasion, while the latter three groups are categorized based on the organs involved. When tumors involved two different structures, they were assigned to the group which would be considered to have the worse prognoses based on previous reports [10 15]. As a result, two cases that involved both the main bronchus and pericardium were included in the pericardium group, two other cases that invaded both the pericardium and diaphragm were included in the diaphragm group. All pathologic information was obtained by reviewing the pathologic reports of each patient. Concerning surgical procedures for chest wall involvement, when the pleura into which the tumor infiltrated was easily mobilized from the subpleural structures, extrapleural resection was selected. In other cases, combined en bloc resection was performed at the discretion of the operating surgeon. All patients routinely underwent systematic hilar and mediastinal lymph node dissection. Whether or not chemotherapy and radiotherapy were administered differed considerably according to the study period, and the chemotherapy regimen also varied widely. In cases of incomplete resection, radiation therapy was performed if possible. Taking the new TNM staging system proposed by IASLC [16, 17] into consideration, the prognoses of following additional patients were also studied. During the same study period at the Aichi Cancer Center Hospital, 62 patients with resected non-small cell lung cancer were diagnosed as pt2 greater than 7 cm, and 49 patients were identified as pt4 with pulmonary metastases in the same lobe using the current staging system. Their tumors did not invade neighboring structures, but they would be assigned to have pt3 disease according to the new staging system. Accordingly, we analyzed their survival for comparison. Statistical Analysis The overall survival rate was calculated using the Kaplan-Meier method. The survival duration was defined from the date of operation to the last known date of survival or all-cause death. The difference in survival rates was tested using the log-rank test. The Cox proportional hazards model was used for multivariate analysis. All statistical analyses were performed using StatView for Windows (version 5.0; SAS Institute, Cary, NC). GENERAL THORACIC

3 GENERAL THORACIC 1078 SAKAKURA ET AL Ann Thorac Surg SUBCATEGORIZATION BY INVOLVED STRUCTURES 2008;86: Results Surgical Outcomes The overall 5-year survival rate of the 196 patients was 39.8%. The survival rate was 41.6% for lobectomies, 37.8% for pneumonectomies, and 22.2% for segmentectomies. There were no significant prognostic differences according to gender, surgical procedure, and tumor histology. There were 6 hospital deaths; causes of death included bleeding, interstitial pneumonia, bacterial pneumonia, and bronchopleural fistula. Completeness of resection crucially affected the prognosis. The 5-year survival rates for 159 patients (81.1%) with complete resections and 37 patients (18.9%) with incomplete resections were 44.0% and 21.6%, respectively (p ). Thirty patients had received induction chemotherapy and radiation therapy. Among them, 9 patients had clinical N2 disease and the postinduction ycn0-1 was obtained in 4 patients. Postoperative adjuvant therapy was performed in 42 patients. Among 159 patients with complete resection, there was no significant prognostic difference between with (n 47) and without (n 112) preoperative or postoperative chemotherapy and radiotherapy (46.8% and 42.9%, respectively; p ). Among 37 patients with incomplete resections, 17 patients treated with chemotherapy and radiotherapy showed a better 5-year survival rate than those who did not receive these therapies (35.3% and 10.0%, respectively; p ). Prognoses Based on Tumor Size and Nodal Status The 5-year survival rates according to tumor size ( 5 cm and 5 cm) were 41.1% and 38.2%, respectively. The prognosis of patients with tumors measuring 5 cm or smaller tended to be better than those with tumors larger than 5 cm, but there was no significant statistical difference between the two groups (p ). The 5-year survival rates for patients with N0, N1, and N2 diseases were 43.5%, 51.2%, and 21.3%, respectively. Patients with N0 disease showed unexpectedly slightly worse outcomes than those with N1 disease, but there was no significant statistical difference between the N0 and N1 diseases. Alternatively, the difference of the survival rates between N0-1 and N2 diseases was significant (45.6% and 21.3%, respectively; p ). Prognoses Based on Involved Neighboring Structures The pleura group had a 5-year survival rate of 54.8%. Seventeen patients had N2 disease. Extrapleural resection was the most preferable intervention and was performed in 49 patients, and combined en bloc resection of the chest wall in 13 patients. Complete resection was achieved in 53 patients (85% of this group); their 5-year survival rate was 53.8%. In the subpleural soft tissue group, the 5-year survival rate was 30.0% and 17 patients had N2 disease. Tumor invasion was limited to the subpleural fat in 22 patients, whereas it extended to the intercostal muscle layer in 28 patients. Extrapleural resection was performed in 21 patients and en bloc resection in 29 patients, including 8 cases of superior sulcus tumor. Thirty-nine patients underwent complete resection (78% of this group), with a survival of 35.9% at 5 years. The rib group showed a 5-year survival rate of 24.0%. No patient had N2 disease. All patients underwent en bloc resection of the chest wall. There were 8 cases of superior sulcus tumor. Complete resection was achieved in 19 patients (76% of this group), with a survival rate of 26.3%. The 5-year survival rate was 48.5% in the main bronchus group, and 6 patients were identified with N2 disease. Operative procedures performed included lobectomy in 19 patients and pneumonectomy in 14. Bronchoplasty was performed in all cases of lobectomy (4 sleeve and 15 wedge resections) and 3 patients underwent Fig 1. Survival curves of all 196 patients based on the neighboring structures involved.

4 Ann Thorac Surg SAKAKURA ET AL ;86: SUBCATEGORIZATION BY INVOLVED STRUCTURES Table 2. Univariate and Multivariate Analyses of Prognostic Factors Univariate Analysis Multivariate Analysis No. of Patients 5-Year Survival (%) p Value HR 95% CI p Value GENERAL THORACIC Resection Complete Incomplete Tumor size 5 cm cm Node status N N Invasion Pleura or Bronchus Others CI confidence interval; HR hazard ratio. Fig 2. Survival curves of all patients based on the subcategorization of pt3 tumors involving neighboring structures (A) and survival curves of patients with pt3n0 (stage IIB) disease (B).

5 GENERAL THORACIC 1080 SAKAKURA ET AL Ann Thorac Surg SUBCATEGORIZATION BY INVOLVED STRUCTURES 2008;86: pneumonectomy (1 sleeve resection and 2 wedge resections). Complete resection was performed in 28 patients (85% of this group), and their survival rate was 54.7%. The pericardium group showed a 5-year survival rate of 21.4%. Five patients had N2 disease. Pneumonectomy was the most common intervention and was performed in 8 patients. Eleven patients (79% of this group) underwent complete resection with a survival of 27.3% at 5 years. The diaphragm group had a 5-year survival rate of 33.3%. Two patients had N2 disease. Combined en bloc resection of the diaphragm was performed in all patients. Complete resection was achieved in 9 patients (75% of this group); their survival rate was 40.4%. structures and those of the two new pt3 diseases: current T2 tumors larger than 7 cm and current T4 tumors with pulmonary metastases in the same lobe. The overall 5-year survival rates of all new pt3 (n 307) and pt3n0 (stage IIB) (n 165) diseases were 36.5% and 42.4%, respectively. The prognoses of pt3 diseases vary considerably (p between all groups) (Fig 3A). Among stage IIB diseases, patients with tumors infiltrating pleura or main bronchus had markedly better prognoses than the other three groups, while patients with tumors involving other neighboring structures demonstrated significantly worse outcomes than the other three groups (p between all groups) (Fig 3B). Subcategorization of Lung Cancer Involving Neighboring Structures Figure 1 shows the survival curves based on the neighboring structures involved. The 5-year survival rate was most favorable in the pleura group, followed in descending order by the main bronchus, diaphragm, subpleural soft tissue, rib, and pericardium groups. The prognoses of the six groups varied considerably (p between all groups), and the pleura and main bronchus groups demonstrated markedly better prognoses than the other groups. The combined pleura and main bronchus groups (n 95) demonstrated significantly better 5-year survival outcome than the other groups (n 101): 52.6% and 27.7%, respectively (p ) (Fig 2A). Among the patients without lymph node metastasis (pt3n0), who were classified as having stage IIB disease according to the current staging system, the survival rates for patients with tumors infiltrating pleura or main bronchus (n 50) and those with tumors involving other neighboring structures (n 58) were 64.0% and 25.9%, respectively (p ) (Fig 2B). Similar results were obtained among the 159 patients with complete resection. The survival rates for the combined pleura and main bronchus groups (n 81) and the other groups (n 78) were 54.3% and 33.3%, respectively (p ), and the survival rates for patients with N0 diseases infiltrating pleura or main bronchus (n 47) and those with N0 diseases involving other neighboring structures (n 44) were 61.7% and 29.5%, respectively (p ). Statistical analyses are summarized in Table 2. The disease could not be subcategorized on the basis of tumor size. In univariate analysis, the patients with N2 disease showed significantly worse prognosis than those with N0-1 diseases (p ), but the significance decreased in multivariate analysis (p ). Multivariate analysis revealed that both the completeness of resection (p ) and the subcategorization of the neighboring structures involved (p ) were much more significant and crucial predictors of pt3 lung cancer involving the neighboring structures. Prognoses of pt3 Diseases Defined Using the New TNM Staging System Figure 3 shows the survival curves of the presently discussed currrent pt3 diseases involving neighboring Comment Until now, analyses of T3 lung cancer involving neighboring structures have often been conducted for each subgroup independently. Therefore, prognostic variation in each subgroup has been demonstrated; however, the optimal method of integrating or subcategorizing these subgroups through which the staging classification adequately reflects the characteristics of tumors has not yet been determined. Detterbeck and Socinski [10] suggested that the heterogeneity of these tumors should be fully recognized in order to establish a more appropriate staging system. Based on their careful review of many previous reports, they concluded that the central-type tumors invading the mediastinal structures and the superior sulcus tumors should be classified as stage IIIA disease even if there was no lymph node metastasis. Table 3 shows the survival rates of patients with complete resection in previous representative reports of T3 lung cancer involving neighboring structures. Concerning tumors invading the chest wall, Magdelienat and colleagues [4] and Facciolo and colleagues [5] reported that tumors with infiltration limited to the parietal pleura have better prognoses than those extending to subpleural structures. In our study, similar results were obtained. In the study by Burkhart and colleagues [7], although there was no significant prognostic difference, the 5-year survival rate tended to be better in tumors with infiltration limited to pleura than those involving deeper structures. Alternatively, Downey and colleagues [6] and Doddoli and colleagues [9] reported that the degree of invasion hardly had any effect on the prognoses, but that the latter heavily depended on the mediastinal nodal involvement. It would be necessary to recognize that the depth of invasion may be an important prognosticator. Regarding tumors involving the main bronchus within 2 cm of the carina, it has been reported that prognoses of this tumor group are relatively favorable [11, 12]. Our surgical outcome was more favorable, which may indicate that the operative techniques for bronchial surgery have been improving. There are few studies dealing with tumors invading only the pericardium. These tumors are often analyzed among those involving mediastinal structures. Patients with such tumors reportedly have a relatively worse prognosis than those with tumors involving the osseous

6 Ann Thorac Surg SAKAKURA ET AL 2008;86: SUBCATEGORIZATION BY INVOLVED STRUCTURES 1081 GENERAL THORACIC Fig 3. Survival curves for pt3 (A) and pt3n0 (stage IIB) (B) diseases defined using the new TNM staging system proposed in chest wall [10]. This may be attributed to the fact that pneumonectomy is likely to be the most frequent intervention for this group [11]. In our cases with complete resection, pneumonectomy was performed for 63% (7 of 11) of this group. Although the tumors involving the diaphragm are defined as T3, this tumor group reportedly has a worse prognosis than the other T3 diseases. Rocco and colleagues [14] and Yokoi and colleagues [15] pointed out that the current staging system for tumors involving the diaphragm should be revised. In the present study, a relatively better outcome was obtained; this may be attributed to the fact that the N2 disease was confirmed in only a few patients in the diaphragm group. Considering the previous reports, it is reasonable to classify these tumors as worse prognostic T3 disease in this study. From the viewpoint of the depth of invasion, it would be considered important to discern whether invasion is limited to or penetrates the pericardium to analyze the pericardium group, and whether invasion is limited to diaphragmatic pleura or reaches the subpleural diaphragmatic muscle layer to analyze the diaphragm group. In this study, however, due to the small sample size of these groups, the depth was not considered for subcategorizing the pericardium and diaphragm groups. Taking an overall view of Table 3, although different studies have different outcomes, we can see that the pleura and main bronchus groups tend to have better outcomes than the other groups, indicating a subcategorization criteria of T3 lung cancer involving neighboring structures. It would be also important to consider that the number of patients with N2 disease in each study may affect the prognoses. In this study, the reason for the slightly worse prognoses of patients with N0 disease compared with those with N1 disease may be due to the small number of patients with N1 disease. However, no prognostic difference between N0 and N1 diseases was also observed in other reports [3, 8]. Currently, a proper clinical evaluation of the depth of invasion is difficult and this tumor characteristic cannot easily be incorporated into the lung cancer staging sys-

7 GENERAL THORACIC 1082 SAKAKURA ET AL Ann Thorac Surg SUBCATEGORIZATION BY INVOLVED STRUCTURES 2008;86: Table 3. Survival of Patients with Completely Resected T3N0-2M0 Lung Cancer T3 Organs First Author [Ref. No.] Year No. of Patients 5-Year Survival (%) Pleura Downey [6] Magdeleinat [4] Facciolo [5] Burkhart [7] Doddoli [9] Present study b 54 Subpleural tissue a Downey [6] Magdeleinat [4] Facciolo [5] Burkhart [7] Doddoli [9] Present study Main bronchus Pitz [11] Riquet [12] Present study Pericardium Pitz [11] c 25 Present study Diaphragm Rocco [14] Yokoi [15] Present study a Including subpleural soft tissue and ribs. b including patients with tumors infiltrating parietal or mediastinal pleura. c including patients with tumors invading mediastinal structures. tem. However, it should be emphasized that the prognostic difference between patients with tumors infiltrating pleura or main bronchus and those with tumors involving other neighboring structures may be more significant than tumor size or even distinction between N0-1 and N2 diseases. In the new TNM staging system proposed by the IASLC in 2007, two different subcategories are subsumed under the new T3 category together with current T3 tumors. In other words, the proposed T3 grouping would include more tumors than the current classification, and would constitute a collection of tumors with quite different characteristics. Because the new staging system has already been formally proposed, our investigation regarding the TNM staging system may likely present both supporting and detracting perspectives. However, the main discussion point arising from our study is that the prognoses of pt3 non-small cell lung cancer involving neighboring structures vary considerably, and it is very important to recognize that this prognostic variation remains significant even after adopting the new staging system (Fig 3). Figure 3 also indicates the reasonableness of reclassifying such T2 and T4 tumors into in the new T3 disease category. We conclude that the subcategorization of resectable lung cancer invading neighboring structures resulted in tumor groups infiltrating pleura or main bronchus, and those involving subpleural structures, pericardium, or diaphragm. Our study, of course, has limitations because of its retrospective design and the relatively small number of cases from a single institution. However, we believe that our proposed subcategorization criteria could provide more information for tumor characteristics, and hence should be validated using larger samples. References 1. International Union Against Cancer. Lung tumours. In: Sobin LH, Wittekind CH, eds. TNM classification of malignant tumours. 5th ed. New York: Wiley-Liss; 1997: Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997;111: Chapelier A, Fadel E, Macchiarini P, et al. Factors affecting long-term survival after en-bloc resection of lung cancer invading the chest wall. Eur J Cardiothorac Surg 2000;18: Magdeleinat P, Alifano M, Benbrahem C, et al. Surgical treatment of lung cancer invading the chest wall: results and prognostic factors. Ann Thorac Surg 2001;71: Facciolo F, Cardillo G, Lopergolo M, Pallone G, Sera F, Martelli M. Chest wall invasion in non-small cell lung carcinoma: a rationale for en bloc resection. J Thorac Cardiovasc Surg 2001;121: Downey RJ, Martini N, Rusch VW, Bains MS, Korst RJ, Ginsberg RJ. Extent of chest wall invasion and survival in patients with lung cancer. Ann Thorac Surg 1999;68: Burkhart HM, Allen MS, Nichols FC III, et al. Results of en bloc resection for bronchogenic carcinoma with chest wall invasion. J Thorac Cardiovasc Surg 2002;123: Matsuoka H, Nishio W, Okada M, Sakamoto T, Yoshimura M, Tsubota N. Resection of chest wall invasion in patients with non-small cell lung cancer. Eur J Cardiothorac Surg 2004;26: Doddoli C, D Journo B, Le Pimpec-Barthes F, et al. Lung cancer invading the chest wall: a plea for en-bloc resection but the need for new treatment strategies. Ann Thorac Surg 2005;80: Detterbeck FC, Socinski MA. IIB or not IIB: the current question in staging non-small cell lung cancer. Chest 1997; 112:

8 Ann Thorac Surg SAKAKURA ET AL 2008;86: SUBCATEGORIZATION BY INVOLVED STRUCTURES 11. Pitz CC, Brutel de la Rivière A, Elbers HR, Westermann CJ, van den Bosch JM. Results of resection of T3 non-small cell lung cancer invading the mediastinum or main bronchus. Ann Thorac Surg 1996;62: Riquet M, Lang-Lazdunski L, Le PB, et al. Characteristics and prognosis of resected T3 non-small cell lung cancer. Ann Thorac Surg 2002;73: Inoue K, Sato M, Fujimura S, et al. Prognostic assessment of 1,310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to J Thorac Cardiovasc Surg 1998;116: Rocco G, Rendina EA, Meroni A, et al. Prognostic factors after surgical treatment of lung cancer invading the diaphragm. Ann Thorac Surg 1999;68: Yokoi K, Tsuchiya R, Mori T, et al. Results of surgical treatment of lung cancer involving the diaphragm. J Thorac Cardiovasc Surg 2000;120: Rami-Porta R, Ball D, Crowley J, et al; on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the T descriptors in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2007;2: Goldstraw P, Crowley J, Chansky K, et al; on behalf of the International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2007;2: The World Health Organization histological typing of lung tumors. 3rd ed. Geneva: World Health Organization; GENERAL THORACIC DISCUSSION DR GAETANO ROCCO (Naples, Italy): I just have one question. What were your criteria for surgical exploration of the mediastinal nodal stations in these patients? Did you perform mediastinoscopy in these patients? DR SAKAKURA: Thank you for your question. We generally use only CT [computed tomographic] scans for clinical N2 diagnosis. Mediastinoscopy is not commonly performed in Japan. We diagnosed a tumor as cn2 when the short-axis diameter of the enlarged lymph node observed in an enhanced CT scan was greater than 1 cm. Thank you. DR FRANK D. DETTERBECK (New Haven, CT): I enjoyed your presentation very much. I can t shake the feeling that there is some confounding factor between the nodal status and the T subgroups. It certainly is odd that the N0 category was worse than the N1 category, and it makes me worried that there are T substages that were more commonly associated with that N0 category, and vice versa for the T stage. I think it s difficult to sort out the 6 different T subgroups when different nodal categories are involved. I know you did a multivariate analysis, but when you did the multivariate analysis, you only did it for the two groupings of T subclassifications. If you redo the multivariate analysis with the 6 different categories of T, I wonder whether you would get a different result. Have you tried that? DR SAKAKURA: Thank you for your valuable comments. There were no significant prognostic differences according to gender, surgical procedures performed, tumor histologies, and postoperative chemotherapy and/or radiation therapy. The reason why the degree of invasion and involved organs takes precedence over the nodal status is very important and essential. I think that the small number of cases may be one reason. We did not perform multivariate analysis as per your suggestion. However, our study findings suggested that the current T3 disease may greatly depend on the degree of invasion and involved organs. Thank you.

The right middle lobe is the smallest lobe in the lung, and

The right middle lobe is the smallest lobe in the lung, and ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,

More information

The T4 category of lung cancer is defined by invasion of the

The T4 category of lung cancer is defined by invasion of the Original Article Results of T4 Surgical Cases in the Japanese Lung Cancer Registry Study Should Mediastinal Fat Tissue Invasion Really be Included in the T4 Category? Shun-ichi Watanabe, MD,* Hisao Asamura,

More information

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis

Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD

More information

Visceral pleural involvement (VPI) of lung cancer has

Visceral pleural involvement (VPI) of lung cancer has Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,

More information

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP

Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans

More information

The accurate assessment of lymph node involvement is

The accurate assessment of lymph node involvement is ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*

More information

Lung cancer is a major cause of cancer deaths worldwide.

Lung cancer is a major cause of cancer deaths worldwide. ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,

More information

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery

ORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji

More information

Lung cancer pleural invasion was recognized as a poor prognostic

Lung cancer pleural invasion was recognized as a poor prognostic Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD

More information

The tumor, node, metastasis (TNM) staging system of lung

The tumor, node, metastasis (TNM) staging system of lung ORIGINAL ARTICLE Peripheral Direct Adjacent Lobe Invasion Non-small Cell Lung Cancer Has a Similar Survival to That of Parietal Pleural Invasion T3 Disease Hao-Xian Yang, MD, PhD,* Xue Hou, MD, Peng Lin,

More information

Prognostic value of visceral pleura invasion in non-small cell lung cancer q

Prognostic value of visceral pleura invasion in non-small cell lung cancer q European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung

More information

Standard treatment for pulmonary metastasis of non-small

Standard treatment for pulmonary metastasis of non-small ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji

More information

Lung cancer with chest wall involvement: Predictive factors of long-term survival after surgical resection

Lung cancer with chest wall involvement: Predictive factors of long-term survival after surgical resection Lung Cancer (2006) 52, 359 364 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/lungcan Lung cancer with chest wall involvement: Predictive factors of long-term survival after

More information

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China

Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,

More information

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer

Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Original Article Validation of the T descriptor in the new 8th TNM classification for non-small cell lung cancer Hee Suk Jung 1, Jin Gu Lee 2, Chang Young Lee 2, Dae Joon Kim 2, Kyung Young Chung 2 1 Department

More information

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG

LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi

More information

Although the international TNM classification system

Although the international TNM classification system Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru

More information

LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II

LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II AUSL BA/4 Ospedale S. Paolo Bari U.O. Complessa di Chirurgia Toracica LA RADIOTERAPIA NEL TRATTAMENTO INTEGRATO DEL CANCRO DEL POLMONE NON MICROCITOMA NSCLC I-II stadio L opinione del chirurgo Francesco

More information

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution

Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Evaluation of the new TNM staging system proposed by the International Association for the Study of Lung Cancer at a single institution Kotaro Kameyama, MD, a Mamoru Takahashi, MD, a Keiji Ohata, MD, a

More information

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy European Journal of Cardio-Thoracic Surgery 41 (2012) 25 30 doi:10.1016/j.ejcts.2011.04.010 ORIGINAL ARTICLE Pulmonary resection for lung cancer with malignant pleural disease first detected at thoracotomy

More information

An Update: Lung Cancer

An Update: Lung Cancer An Update: Lung Cancer Andy Barlow Consultant in Respiratory Medicine Lead Clinician for Lung Cancer (West Herts Hospitals NHS Trust) Lead for EBUS-Harefield Hospital (RB&HFT) Summary Lung cancer epidemiology

More information

Node-Negative Non-small Cell Lung Cancer

Node-Negative Non-small Cell Lung Cancer ORIGINAL ARTICLE Node-Negative Non-small Cell Lung Cancer Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy, RMRA, Jocelyn McLean, RN, MN, and

More information

Lung Cancer Invading the Chest Wall: A Plea for En-Bloc Resection but the Need for New Treatment Strategies

Lung Cancer Invading the Chest Wall: A Plea for En-Bloc Resection but the Need for New Treatment Strategies Lung Cancer Invading the Chest Wall: A Plea for En-Bloc Resection but the Need for New Treatment Strategies Christophe Doddoli, MD, Benoit D Journo, MD, Françoise Le Pimpec-Barthes, MD, Antoine Dujon,

More information

Factors affecting survival in non-small cell lung cancer invading the chest wall.

Factors affecting survival in non-small cell lung cancer invading the chest wall. Biomedical Research 2017; 28 (6): 2673-2678 ISSN 0970-938X www.biomedres.info Factors affecting survival in non-small cell lung cancer invading the chest wall. Abidin Sehitogullari 1, Yusuf Aydemir 2*,

More information

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis

Although ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,

More information

According to the current International Union

According to the current International Union Treatment of Stage II Non-small Cell Lung Cancer* Walter J. Scott, MD, FCCP; John Howington, MD, FCCP; and Benjamin Movsas, MD Based on clinical assessment alone, patients with stage II non-small cell

More information

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival

Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,

More information

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010

Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 LSU HEALTH SCIENCES CENTER NSCLC Guidelines Feist-Weiller Cancer Center Molly Boyd, MD Glenn Mills, MD Syed Jafri, MD 1/1/2010 Initial Evaluation/Intervention: 1. Pathology Review 2. History and Physical

More information

Lymph node dissection for lung cancer is both an old

Lymph node dissection for lung cancer is both an old LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko

More information

Visceral pleura invasion (VPI) was adopted as a specific

Visceral pleura invasion (VPI) was adopted as a specific ORIGINAL ARTICLE Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival Its Implications for the Forthcoming TNM Staging Based on a Large-Scale Nation-Wide Database Junji Yoshida,

More information

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis

In 1989, Deslauriers et al. 1 described intrapulmonary metastasis ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,

More information

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is

In non small cell lung cancer, metastasis to lymph nodes, the N factor, is Okada et al General Thoracic Surgery Border between N1 and N2 stations in lung carcinoma: Lessons from lymph node metastatic patterns of lower lobe tumors Morihito Okada, MD, PhD Toshihiko Sakamoto, MD,

More information

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer

Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,

More information

Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers

Applicability of the revised International Association for the Study of Lung Cancer staging system to operable non-small-cell lung cancers European Journal of Cardio-thoracic Surgery 36 (2009) 1031 1036 www.elsevier.com/locate/ejcts Applicability of the revised International Association for the Study of Lung Cancer staging system to operable

More information

Surgical resection is the first treatment of choice for

Surgical resection is the first treatment of choice for Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,

More information

Visceral pleural invasion (VPI) of lung cancer has been

Visceral pleural invasion (VPI) of lung cancer has been ORIGINAL ARTICLE Visceral Pleural Invasion Classification in Non Small- Cell Lung Cancer in the 7th Edition of the Tumor, Node, Metastasis Classification for Lung Cancer: Validation Analysis Based on a

More information

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018

HISTORY SURGERY FOR TUMORS WITH INVASION OF THE APEX 15/11/2018 30 EACTS Annual Meeting Barcelona, Spain 1-5 October 2016 SURGERY FOR TUMORS WITH INVASION OF THE APEX lung cancer of the apex of the chest involving any structure of the apical chest wall irrespective

More information

The 8th Edition Lung Cancer Stage Classification

The 8th Edition Lung Cancer Stage Classification The 8th Edition Lung Cancer Stage Classification Elwyn Cabebe, M.D. Medical Oncology, Hematology, and Hospice and Palliative Care Valley Medical Oncology Consultants Director of Quality, Medical Oncology

More information

Lung cancer is one of the leading causes of death in most

Lung cancer is one of the leading causes of death in most ORIGINAL ARTICLE Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in Demographic and Prognosis Changes Over Decade Noriyoshi Sawabata, MD, PhD,* Etsuo Miyaoka, PhD, Hisao Asamura, MD, PhD,

More information

Mediastinal Staging. Samer Kanaan, M.D.

Mediastinal Staging. Samer Kanaan, M.D. Mediastinal Staging Samer Kanaan, M.D. Overview Importance of accurate nodal staging Accuracy of radiographic staging Mediastinoscopy EUS EBUS Staging TNM Definitions T Stage Size of the Primary Tumor

More information

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis

Pulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;

More information

In the mid 1970s, visceral pleural invasion (VPI) was included

In the mid 1970s, visceral pleural invasion (VPI) was included ORIGINAL ARTICLE Tumor Invasion of Extralobar Soft Tissue Beyond the Hilar Region Does Not Affect the Prognosis of Surgically Resected Lung Cancer Patients Hajime Otsuka, MD,* Genichiro Ishii, MD, PhD,*

More information

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data

Revisiting Stage IIIB and IV Non-small Cell Lung Cancer. Analysis of the Surveillance, Epidemiology, and End Results Data CHEST Revisiting Stage IIIB and IV Non-small Cell Lung Cancer Analysis of the Surveillance, Epidemiology, and End Results Data William N. William, Jr, MD; Heather Y. Lin, PhD; J. Jack Lee, PhD; Scott M.

More information

Video-Mediastinoscopy Thoracoscopy (VATS)

Video-Mediastinoscopy Thoracoscopy (VATS) Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin

More information

A comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer

A comparison of the proposed classifications for the revision of N descriptors for non-small-cell lung cancer European Journal of Cardio-Thoracic Surgery 49 (2016) 580 588 doi:10.1093/ejcts/ezv134 Advance Access publication 18 April 2015 ORIGINAL ARTICLE Cite this article as: Lee GD, Kim DK, Moon DH, Joo S, Hwang

More information

Staging of lung cancer based on the TNMclassification

Staging of lung cancer based on the TNMclassification The Prognostic Impact of Main Bronchial Lymph Node Involvement in Non-Small Cell Lung Carcinoma: Suggestions for a Modification of the Staging System Yoshihisa Shimada, MD, Masahiro Tsuboi, MD, PhD, Hisashi

More information

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum

T3 NSCLC: Chest Wall, Diaphragm, Mediastinum for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No

More information

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease

Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately

More information

Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer

Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer ORIGINAL ARTICLE Long-Term Outcome and Late Recurrence in Patients with Completely Resected Stage IA Non-small Cell Lung Cancer Ryo Maeda, MD,* Junji Yoshida, MD,* Genichiro Ishii, MD, Keiju Aokage, MD,*

More information

Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma

Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma 244 Pleural lavage cytology as an independent prognostic factor in non-small cell lung cancer patients with stage I disease and adenocarcinoma DAISUKE HOKKA 1, KAZUYA UCHINO 2, KENTA TANE 2, HIROYUKI OGAWA

More information

The 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice

The 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice The 8th Edition of the TNM Classification for Lung Cancer Background, Innovations and Implications for Clinical Practice University of Torino Lecture 28th June 2017 Torino, Italy Ramón Rami-Porta Thoracic

More information

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City

Role of Surgery in Management of Non Small Cell Lung Cancer. Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Role of Surgery in Management of Non Small Cell Lung Cancer Dr. Ahmed Bamousa Consultant thoracic surgery Prince Sultan Military Medical City Introduction Surgical approach Principle and type of surgery

More information

The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma

The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,

More information

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer

Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae

More information

Small cell lung cancer (SCLC), which represents 20%

Small cell lung cancer (SCLC), which represents 20% ORIGINAL ARTICLES: GENERAL THORACIC Surgical Results for Small Cell Lung Cancer Based on the New TNM Staging System Masayoshi Inoue, MD, Shinichiro Miyoshi, MD, Tsutomu Yasumitsu, MD, Takashi Mori, MD,

More information

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology

Slide 1. Slide 2. Slide 3. Investigation and management of lung cancer Robert Rintoul. Epidemiology. Risk factors/aetiology Slide 1 Investigation and management of lung cancer Robert Rintoul Department of Thoracic Oncology Papworth Hospital Slide 2 Epidemiology Second most common cancer in the UK (after breast). 38 000 new

More information

Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial

Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Comparison of complete and minimal mediastinal lymph node dissection for non-small cell lung cancer: Results of a prospective randomized trial Junhua Zhang*,

More information

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer

Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Intraoperative pleural lavage cytology after lung resection as an independent prognostic factor for staging lung cancer Yasushi Shintani, MD, hd, a Mitsunori Ohta, MD, hd, a Teruo Iwasaki, MD, hd, a Naoki

More information

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size

Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size GENERAL THORACIC Visceral Pleural Invasion Is Not Predictive of Survival in Patients With Lung Cancer and Smaller Tumor Size Elizabeth David, MD, Peter F. Thall, PhD, Neda Kalhor, MD, Wayne L. Hofstetter,

More information

The roles of adjuvant chemotherapy and thoracic irradiation

The roles of adjuvant chemotherapy and thoracic irradiation Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,

More information

Lung cancer is the leading cause of cancer deaths worldwide.

Lung cancer is the leading cause of cancer deaths worldwide. ORIGINAL ARTICLE Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non Small-Cell Lung Cancer Jung-Jyh Hung, MD, PhD,* Wen-Juei Jeng, MD, Wen-Hu

More information

Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer

Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer Jpn. J. Clin. Oncol. 198, 1 (), 7-1 Prognostic Significance of Extranodal Cancer Invasion of Mediastinal Lymph Nodes in Lung Cancer KEIICHI SUEMASU, M.D. AND TSUGUO NARUKE, M.D. Department of Surgery,

More information

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer

Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Original Article Clinical significance of skipping mediastinal lymph node metastasis in N2 non-small cell lung cancer Jun Zhao*, Jiagen Li*, Ning Li, Shugeng Gao Department of Thoracic Surgery, National

More information

CHEST WALL INVASION IN NON SMALL CELL LUNG CARCINOMA: A RATIONALE FOR EN BLOC RESECTION

CHEST WALL INVASION IN NON SMALL CELL LUNG CARCINOMA: A RATIONALE FOR EN BLOC RESECTION CHEST WALL INVASION IN NON SMALL CELL LUNG CARCINOMA: A RATIONALE FOR EN BLOC RESECTION Francesco Facciolo, MD a Giuseppe Cardillo, MD a Michele Lopergolo, MD a Guido Pallone, MD a Francesco Sera, DSc

More information

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER

MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo

More information

Bronchogenic Carcinoma

Bronchogenic Carcinoma A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most

More information

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer

North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer THIS DOCUMENT IS North of Scotland Cancer Network Clinical Management Guideline for Non Small Cell Lung Cancer [Based on WOSCAN NSCLC CMG with further extensive consultation within NOSCAN] UNCONTROLLED

More information

Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer

Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer Post-Induction PET Does Not Correlate with Persistent Nodal Disease or Overall Survival in Surgically Treated Stage IIIA Non-Small Cell Lung Cancer R. Taylor Ripley, Kei Suzuki, Kay See Tan, Manjit Bains,

More information

Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer

Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer CHEST Original Research Prognostic Significance of the Extent of Visceral Pleural Invasion in Completely Resected Node-Negative Non-small Cell Lung Cancer Jung-Jyh Hung, MD, PhD ; Wen-Juei Jeng, MD ; Wen-Hu

More information

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer

The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:

More information

Pathologic Lymph Node Staging Practice and Stage- Predicted Survival After Resection of Lung Cancer

Pathologic Lymph Node Staging Practice and Stage- Predicted Survival After Resection of Lung Cancer ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer

Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer Original Article Therapeutic value of lymph node dissection for right middle lobe non-small-cell lung cancer Hiroaki Kuroda 1,2, Yukinori Sakao 1,2, Mingyon Mun 2, Noriko Motoi 3, Yuichi Ishikawa 3, Ken

More information

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09

Lung Cancer Imaging. Terence Z. Wong, MD,PhD. Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Lung Cancer Imaging Terence Z. Wong, MD,PhD Department of Radiology Duke University Medical Center Durham, NC 9/9/09 Acknowledgements Edward F. Patz, Jr., MD Jenny Hoang, MD Ellen L. Jones, MD, PhD Lung

More information

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis

Prognostic factors of postrecurrence survival in completely resected stage I non-small cell lung cancer with distant metastasis < A supplementary figure and table are published online only at http://thx.bmj.com/content/ vol65/issue3. 1 Institute of Clinical Medicine, National Yang-Ming University, 2 Department of Surgery, Cathay

More information

The surgeon: new surgical aproaches

The surgeon: new surgical aproaches The surgeon: new surgical aproaches Paul Van Schil, MD Department of Thoracic and Vascular Surgery Antwerp University, Belgium no disclosures, no conflict of interest Malignant pleural mesothelioma: clinical,

More information

P sumed to have early lung disease with a favorable

P sumed to have early lung disease with a favorable Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,

More information

Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy

Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy Survival Comparison of Adenosquamous, Squamous Cell, and Adenocarcinoma of the Lung After Lobectomy David T. Cooke, MD, Danh V. Nguyen, PhD, Ying Yang, MS, Steven L. Chen, MD, MBA, Cindy Yu, MD, and Royce

More information

Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer

Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Ann Thorac Cardiovasc Surg 2011; 17: 58 62 Case Report Prognostic Factors of Pathologic Stage IB Non-small Cell Lung Cancer Motoki Yano, MD, Hidefumi Sasaki, MD, Satoru Moriyama, MD, Osamu Kawano MD, Yu

More information

Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer. Quick Reference Chart and Diagrams

Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer. Quick Reference Chart and Diagrams CHEST Special Features Seventh Edition of the Cancer Staging Manual and Stage Grouping of Lung Cancer Quick Reference Chart and Diagrams Omar Lababede, MD ; Moulay Meziane, MD ; and Thomas Rice, MD, FCCP

More information

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas

Pulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS

More information

L cancer-related deaths in Japan. The number of patients

L cancer-related deaths in Japan. The number of patients Extended Resection of the Left Atrium, Great Vessels, or Both for Lung Cancer Ryosuke Tsuchiya, MD, Hisao Asamura, MD, Haruhiko Kondo, MD, Tomoyuki Goya, MD, and Tsuguo Naruke, MD Division of Thoracic

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566

More information

Induction chemotherapy followed by surgical resection

Induction chemotherapy followed by surgical resection Surgical Resection for Residual N 2 Disease After Induction Chemotherapy Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Matthew A. Levin, BS, David E. Becker, MA, Roger Keresztes, MD, and Nasser

More information

Complete surgical excision remains the greatest potential

Complete surgical excision remains the greatest potential ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,

More information

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib

Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Case Report Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib Ichiro Sakanoue 1, Hiroshi Hamakawa 1, Reiko Kaji 2, Yukihiro Imai 3, Nobuyuki Katakami 2, Yutaka Takahashi 1 1 Department

More information

Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis

Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Original Article Stage I synchronous multiple primary non-small cell lung cancer: CT findings and the effect of TNM staging with the 7th and 8th editions on prognosis Jingxu Li, Xinguan Yang, Tingting

More information

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW

Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC. Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW Correlation of pretreatment surgical staging and PET SUV(max) with outcomes in NSCLC Giancarlo Moscol, MD PGY-5 Hematology-Oncology UTSW BACKGROUND AJCC staging 1 gives valuable prognostic information,

More information

Lung cancer is a prevalent health problem worldwide. It is the leading cause

Lung cancer is a prevalent health problem worldwide. It is the leading cause Prognostic factors in resected stage I non small cell lung cancer with a diameter of 3 cm or less: Visceral pleural invasion did not influence overall and disease-free survival Jung-Jyh Hung, MD, a,b Chien-Ying

More information

Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen, Jan-Willem J.

Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen, Jan-Willem J. Characteristics of lung cancers detected in the randomized NELSON lung cancer screening trial Nanda Horeweg, Carlijn M. van der Aalst, Erik Thunnissen, Kristiaan Nackaerts, Carla Weenink, Harry J.M. Groen,

More information

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko Higashiyama, MD, PhD, Tomio Nakayama, MD, PhD,

More information

The prognostic significance of central fibrosis of adenocarcinoma

The prognostic significance of central fibrosis of adenocarcinoma Prognostic Significance of the Size of Central Fibrosis in Peripheral Adenocarcinoma of the Lung Kenji Suzuki, MD, Tomoyuki Yokose, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, Kenro Takahashi, MD, Kanji

More information

Small-cell lung cancer (SCLC) represents approximately

Small-cell lung cancer (SCLC) represents approximately Original Article Bolstering the Case for Lobectomy in Stages I, II, and IIIA Small-Cell Lung Cancer Using the National Cancer Data Base Susan E. Combs, MA, Jacquelyn G. Hancock, BS, Daniel J. Boffa, MD,

More information

The Itracacies of Staging Patients with Suspected Lung Cancer

The Itracacies of Staging Patients with Suspected Lung Cancer The Itracacies of Staging Patients with Suspected Lung Cancer Gerard A. Silvestri, MD,MS, FCCP Professor of Medicine Medical University of South Carolina Charleston, SC silvestri@musc.edu Staging Lung

More information

Imaging of Lung Cancer: A Review of the 8 th TNM Staging System

Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Imaging of Lung Cancer: A Review of the 8 th TNM Staging System Travis S Henry, MD Associate Professor of Clinical Radiology Cardiac and Pulmonary Imaging Section University of California, San Francisco

More information

Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer

Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Prognostic Factors in Resected Satellite Nodule T4 Non-Small Cell Lung Cancer Jagan Rao, FRCS(C-Th), Rana A. Sayeed, FRCS(C-Th), Sandra Tomaszek, Stefan Fischer, MD, Shaf Keshavjee, MD, FRCSC, and Gail

More information

MEDIASTINAL STAGING surgical pro

MEDIASTINAL STAGING surgical pro MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical

More information

Cheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda

Cheng-Yang Song, Takehiro Sakai, Daisuke Kimura, Takao Tsushima, Ikuo Fukuda Original Article Comparison of perioperative and oncological outcomes between video-assisted segmentectomy and lobectomy for patients with clinical stage IA non-small cell lung cancer: a propensity score

More information

The tumor-node-metastasis (TNM) system is

The tumor-node-metastasis (TNM) system is LUNG CARCINOMA STAGING PROBLEMS Philip T. Cagle, MD a,b, * KEYWORDS Lung Carcinoma Staging Tumor-node-metastasis TNM system ABSTRACT The tumor-node-metastasis (TNM) system is the most commonly used staging

More information

TNM classifications have been established for various

TNM classifications have been established for various Lymphogenous and Hematogenous Metastasis of Thymic Epithelial Tumors Kazuya Kondo, MD, PhD, and Yasumasa Monden, MD, PhD Department of Oncological and Regenerative Surgery, School of Medicine, University

More information

Since the introduction of low-dose helical computed tomography

Since the introduction of low-dose helical computed tomography Original Article Prognostic Impact of Tumor Size Eliminating the Ground Glass Opacity Component Modified Clinical T Descriptors of the Tumor, Node, Metastasis Classification of Lung Cancer Shota Nakamura,

More information